Last updated on August 2019

A Study of RO7105705 in Patients With Moderate Alzheimer's Disease

Brief description of study

This Phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group study will evaluate the clinical efficacy, safety, pharmacokinetics, and pharmacodynamics of RO7105705 in patients with moderate AD. The study consists of a screening period, a double-blind treatment period, an optional open-label extension (OLE) period, and a safety follow-up period.

Clinical Study Identifier: NCT03828747

Find a site near you

Start Over

Pharmacology Research Institute

Los Alamitos, CA United States
  Connect »

Collaborative Neuroscience Network, Inc.

Garden Grove, CA United States
  Connect »